Research Triangle Park, N.C., February 5, 2008 While on scholarly leave from North Carolina State University, Dr. Marian McCord has joined Entegrion¹s research and development team. Entegrion is a therapeutic development company that specializes in developing technologies for hemorrhage control, wound management and associated tissue repair. Dr. McCord will work with Entegrion¹s chief science officer and inventor of the Stasilon technologies, Dr. Thomas Fischer, on research and development of new wound care products based on medical textiles.
Dr. McCord is an associate professor in the Joint Department of Biomedical Engineering with UNC- Chapel Hill and NCSU. Additionally, she serves as the director of the Tissue Engineering Laboratory, co-director of the Atmospheric Plasma Laboratory, and associate professor in the textile engineering department, all in the College of Textiles at NCSU.
We look forward to working with Marian in her areas of expertise in fiber and polymer science and surface modification, said Dr. Thomas Fischer. Her specialized skills will strengthen Entegrion¹s development team as we work to bring together hematology and textile engineering.
Dr. McCord received her B.S. in Biomedical Engineering from Brown University and her M.S. in Bioengineering and Ph.D. in Textiles and Polymer Science from Clemson University.
About Entegrion
Entegrion is a life sciences company that selectively integrates synergistic technologies with those in its patent portfolio for development of novel devices and drugs for hemorrhage control, wound management, and associated tissue repair. The company is based in North Carolina¹s Research Triangle Park, and is the inventor of StasilonTM the FDA approved hemostatic medical textile technology approved for use both by prescription and by consumers from which multiple hemorrhage control products are made. Building upon technologies licensed from the University of North Carolina, Entegrion¹s portfolio includes platelet-derived platform technologies that are being developed as topical gels and sprays for tissue repair, infusible hemostatic agents for the control of internal hemorrhage, and novel vehicles for delivery of drugs to targeted tumors and other sites of internal bleeding. For more information, visit www.entegrion.com.
